EWS & EVENTS
Shattuck’s ARC platform

Shattuck’s ARC platform was highlighted in a presentation at ASCO Breakthrough (October 11-13, 2019 in Bangkok, Thailand). An overview of the ARC platform and its unique features in comparison to monoclonal antibodies, as well as the Phase I study of SL-279252 (ClinicalTrials.gov Identifier: NCT03894618) were discussed by Dr. Johanna Bendell, Chief Development Officer of Sarah Cannon Research Institute, during her presentation on Bispecific Antibodies as part of the panel discussion on New Molecular and Immuno-Oncologic Based Therapeutics.

MIGHT ALSO LIKE
YOU MIGHT ALSO LIKE
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Fromm et.al Journal for ImmunoTherapy of Cancer, 18 December 2018

Read more
Taylor Schreiber to speak at the 2020 CD47/Sirp a Summit - March 18-19th in Boston

Shattuck Labs CSO and Co-Founder to give presentation: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge…

Read more